Article · 2013
Editor
Crispin R Dass
School of Biomedical and Health Sciences, Victoria University, Australia
About
As published by the journal they serve.
Dr. Crispin R. Dass [(BAppSci (Hons), PhD)] has 17 years of cell and molecular biology research experience, mainly focusing on oncological R&D. He completed his secondary education in California, before moving to Australia for his tertiary education. His research is on systems at various levels-in silico, in vitro, in vivo, ADME/Tox, clinical, and also in biomedical education fostering passion in young scientists. His forte lies in formulation of nanoparticulate drug delivery systems for new and old compounds for cancer therapy. He has worked on projects for Johnson & Johnson, GlaxoSmithKline, Amgen, and Novartis. His extensive experience is documented in his 120 papers to date, with publications in Nature Medicine, Journal of the National Cancer Institute, Biomaterials, Nucleic Acids Research, Cancer, and Journal of Controlled Release. He is currently on the editorial board of 4 other journals in his field, and has been invited to chair sessions and to give keynote lectures at national and international conferences. Based currently in St Albans (Melbourne, Australia), he has research links within Australia and in Thailand, Fiji, USA, China, South Korea, Japan, Iran and India.
Research interests
Journals they serve
The seats these journals name them in.
- Metabolomics:Open AccessEditor
- Metabolomics:Open AccessEditorial Board Member
Articles we hold
Articles in the journals they serve whose byline carries this name.
Article
Marine Biomining for Better Biopolymers than Chitosan
Article · 2014
Cardiomyocyte apoptosis versus autophagy with prolonged Doxorubicin treatment: Comparison with osteosarcoma cells
Article · 2014
The ever increasing role of PEDF in bone biology and pathology: Regeneration and cancer as examples
Article · 2011
The search for safe compounds, robust assays and better drug delivery systems for improved anticancer activity
Article · 2011
The search for safe compounds, robust assays and better drug delivery systems for improved anticancer activity
This page holds what the journals publish about this profile: no contact details, and nothing gathered from anywhere else. Ask us to correct or remove this profile.
